Strensiq Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Strensiq market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to increasing patient advocacy, positive clinical trial outcomes, expanded physician education programs, support from advocacy groups, and a growing focus on pediatric indications.

Growth during the market's forecast period can be attributed to increasing investments in research and development, advancements in medical technology, and a growing focus on personalized treatments. Major trends during this period include advances in patient monitoring, the dominance of monoclonal antibodies, the rise of cancer immunotherapies, advancements in biologic-based vaccines, and enhanced data-driven approaches in treatment planning and outcomes.

The growing emphasis on rare disease treatments is expected to drive the expansion of the Strensiq market in the future. Rare disease treatments are specialized medical interventions designed to address conditions that affect a small percentage of the population, often requiring unique therapies or medications that may not be widely accessible. The increasing attention to rare disease treatment is driven by factors such as precision medicine, unmet patient needs, regulatory incentives, and opportunities for healthcare innovation. Strensiq, an enzyme replacement therapy, plays a key role in treating hypophosphatasia, a rare genetic disorder that affects bone mineralization, by replenishing the deficient alkaline phosphatase enzyme. This treatment helps improve bone health, reduce skeletal abnormalities, and enhance the overall quality of life for patients suffering from this debilitating condition. For example, in September 2023, the Cystic Fibrosis Trust reported that in the UK, the number of people registered with cystic fibrosis surpassed 11,000 in 2022, showing a significant increase from the previous year. This increasing focus on rare disease treatment is contributing to the growth of the Strensiq market.

Rising healthcare investments are also expected to accelerate the growth of the Strensiq market. Healthcare investments involve the allocation of financial resources to improve healthcare systems, technologies, infrastructure, and services, with the goal of enhancing medical access, patient outcomes, and advancing innovation in treatments and preventive care. These investments are rising due to global health challenges, advancements in medical technology, increasing demand for better healthcare access, and the need to address aging populations and chronic diseases. Healthcare investments support Strensiq by driving research and development, as well as improving accessibility to this enzyme replacement therapy, which in turn ensures better treatment outcomes for hypophosphatasia patients and advances medical breakthroughs in the management of rare diseases. For instance, a report by the Centers for Medicare & Medicaid Services in September 2024 revealed that in 2022, healthcare investments in the US saw significant growth, with total health expenditures reaching $4.5 trillion, a 4.1% increase from the previous year. Therefore, the rise in healthcare investments is playing a role in expanding the Strensiq market.

The growing adoption of personalized medicine is another key factor driving the Strensiq market. Personalized medicine tailors medical treatments and healthcare strategies to the individual characteristics of each patient, such as their genetic profile, lifestyle, and environment, enhancing the effectiveness of treatments while minimizing side effects. The increasing trend of personalized medicine allows for more customized and effective healthcare interventions. Strensiq supports personalized medicine by offering targeted enzyme replacement therapy for patients with hypophosphatasia, enabling customized treatment plans that address specific genetic mutations and the varying severity of the disease in individual patients. This personalized approach leads to improved treatment outcomes and quality of life for patients. According to the Personalized Medicine Coalition, in 2022, 12 new personalized medicines were approved, making up about 34% of all newly approved therapies, a notable increase compared to the previous year. Therefore, the rise in personalized medicine is a driving factor for the growth of the Strensiq market.

The key company operating in the strensiq market is AstraZeneca plc.

North America was the largest region in the strensiq market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in strensiq report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the strensiq market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Strensiq is a prescription medication containing asfotase alfa, a targeted enzyme replacement therapy designed specifically for treating hypophosphatasia (HPP). It is administered as a subcutaneous injection several times a week to replace the deficient enzyme in patients with HPP, helping to improve bone mineralization and overall skeletal health.

The main formulations of Strensiq include subcutaneous injections and single-use vials. The subcutaneous injection method involves administering the medication directly into the fat and tissue beneath the skin. Strensiq is used for various clinical indications, including perinatal or neonatal-onset HPP, infantile-onset HPP, childhood-onset HPP, and adult-onset HPP. It is distributed through retail and online pharmacies, serving both pediatric and adult patients.

The strensiq market research report is one of a series of new reports that provides strensiq market statistics, including strensiq industry global market size, regional shares, competitors with a strensiq market share, detailed strensiq market segments, market trends and opportunities, and any further data you may need to thrive in the strensiq industry. This strensiq market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The strensiq market consists of sales of subcutaneous injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.